This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ventas, Inc. is a healthcare real estate investment trust (REIT) that is primarily engaged in acquisition and ownership of senior housing, R&I and healthcare properties, and leasing them to unaffiliated tenants or operating them through independent third-party managers. Ventas offers MOB management, leasing, marketing, facility development and advisory services to well-rated hospitals and health systems throughout the United States through its ownership interest in PMB Real Estate Services LLC and the company’s subsidiary, Lillibridge Healthcare Services, Inc. It also makes secured and non-mortgage loans and other investments relating to senior housing and healthcare properties or operators.
Ventas (VTR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Ventas (VTR) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ventas (VTR) Q4 FFO Match Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of 0% and 1.43%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat in the Offing for Ventas (VTR) in Q4 Earnings?
by Zacks Equity Research
Favorable SHOP operating trends, healthy demand for life-science real estate assets and accretive investments are likely to have benefited Ventas' (VTR) Q4 earnings.
Is a Surprise Coming for Ventas (VTR) This Earnings Season?
by Zacks Equity Research
Ventas (VTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Ahead of Ventas (VTR) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Ventas (VTR) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Top 5 Dividend-Paying Stocks Set to Beat on Earnings Next Week
by Nalak Das
We have narrowed our search to five dividend-paying large-cap stocks that are poised to beat on earnings next week. These are: WM, QSR, TAP, LDOS, VTR.
Will Solid Transaction Growth Aid Euronet's (EEFT) Q4 Earnings?
by Zacks Equity Research
Euronet's (EEFT) Q4 results are expected to reflect the benefits of an expanding POS acquiring business and growth in international money transfers. Inflationary headwinds are likely to have escalated costs.
Alexandria's (ARE) Q4 AFFO Misses Estimates, '24 View Issued
by Zacks Equity Research
Alexandria's (ARE) Q4 results reflect lower-than-anticipated AFFO per share despite a rise in revenues. It has also issued its 2024 outlook.
SL Green's (SLG) Q4 FFO Lag Estimates, 2024 View Raised
by Zacks Equity Research
SL Green's (SLG) Q4 FFO misses estimates on lower-than-anticipated revenues. However, same-store cash net operating income improves year over year.
Crown Castle's (CCI) Q4 AFFO Beat Estimate, Revenues Down Y/Y
by Zacks Equity Research
Crown Castle's (CCI) Q4 results outshine estimates on better-than-anticipated revenues. However, high interest expense is a concern. It has maintained its 2024 outlook.
Crown Castle's (CCI) Q4 AFFO Beat, Site-Rental Revenues Up
by Zacks Equity Research
Crown Castle's (CCI) Q4 earnings outshine estimates on elevated fiber segment revenues. Site-rental revenues grow year over year, aiding the top line.
Here's Why Investors Should Retain Ventas (VTR) Stock for Now
by Zacks Equity Research
A rise in healthcare spending by senior citizens and accretive investments in the research portfolio bode well for Ventas (VTR). However, dependence on a few tenants and high interest rates are woes.
Ventas' (VTR) Q3 FFO Beat on SHOP NOI Growth, '23 View Revised
by Zacks Equity Research
Ventas's (VTR) Q3 earnings outshine estimates on better-than-anticipated revenues. The same-store cash NOI rises year over year on strong performance across the portfolio. The company has revised its 2023 outlook.
Compared to Estimates, Ventas (VTR) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Ventas (VTR) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Is a Beat in the Offing for Ventas (VTR) in Q3 Earnings?
by Zacks Equity Research
Favorable senior housing operating portfolio operating trends, robust demand for life-science real-estate assets and accretive investments are likely to have benefited Ventas' (VTR) Q3 earnings.
Regency Centers (REG) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Healthy demand for Regency Centers' (REG) shopping centers and gains from accretive acquisitions are likely to have benefited its Q3 earnings. However, higher interest rates might have ailed.
Factors to Impact Innovative Industrial's (IIPR) Q3 Earnings
by Zacks Equity Research
With the cannabis industry gaining prominence, Innovative Industrial's (IIPR) investments in such properties are likely to have aided its Q3 performance, though high expenses might have played a spoilsport.
Key Factors to Impact Boston Properties' (BXP) Q3 Earnings
by Zacks Equity Research
Healthy demand for Boston Properties' (BXP) premium office and life-science assets is likely to have benefited its Q3 earnings. However, higher interest expenses might have hurt it.
What's in the Offing for Host Hotels (HST) in Q3 Earnings?
by Zacks Equity Research
Host Hotels' (HST) Q3 earnings are likely to have benefited from the continued strength in group travel and business transient demand. However, higher interest expenses might have hurt it.
Is a Beat in the Cards for Welltower (WELL) in Q3 Earnings?
by Zacks Equity Research
Welltower's (WELL) Q3 earnings are likely to have benefited from the rise in senior citizen's healthcare expenditure and accretive capital deployment activity.
Is a Beat in Store for Healthpeak (PEAK) in Q3 Earnings?
by Zacks Equity Research
Robust demand for Healthpeak's (PEAK) lab assets and a rise in senior citizen's healthcare expenditure are expected to have benefited its Q3 earnings.
Getty Realty (GTY) Tops Q3 FFO and Revenue Estimates
by Zacks Equity Research
Getty Realty (GTY) delivered FFO and revenue surprises of 1.79% and 9.33%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Investors Should Retain Ventas (VTR) Stock for Now
by Zacks Equity Research
A rise in healthcare spending by senior citizens and accretive investments in the research portfolio bode well for Ventas (VTR). However, dependence on a few tenants and high interest rates are woes.
Ventas (VTR) Partners With Operators for Senior Housing Growth
by Zacks Equity Research
Ventas (VTR) teams up with expert operators to enhance the performance of 26 independent living communities.
Medical Properties (MPW) Beats on Q2 FFO, Narrows '23 View
by Zacks Equity Research
Medical Properties' (MPW) Q2 results reflect lower-than-anticipated revenues. Higher interest expenses during the quarter act as a dampener. The company narrows its 2023 outlook.